Expert Ratings for Aclaris Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have provided bullish ratings for Aclaris Therapeutics (NASDAQ:ACRS) within the last quarter, with an average price target of $36.0 versus the current price of $7.39. This average price target has increased by 125.0% over the past month.
September 19, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bullish ratings and a significantly higher price target suggest potential upside for Aclaris Therapeutics.
The bullish ratings and significantly higher price target provided by analysts suggest they expect Aclaris Therapeutics' stock price to rise in the short term. This could potentially lead to an increase in the stock's price as investors react to these positive expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100